Effectiveness and safety of blonanserin monotherapy for first-episode schizophrenia with and without prominent negative symptoms: A prospective study

doi:10.5498/wjp.v15.i5.103701

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (361)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

HTML

141

Figures (1-3)

Tables (1-2)

Sum=205

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=124

Publishing Process of This Article

Item

Count

Browse

Download

Sum=23

May 19, 2025 (publication date) through May 6, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Psychiatry. May 19, 2025; 15(5): 103701
Published online May 19, 2025. doi: 10.5498/wjp.v15.i5.103701

Full Size Figure Download Figure

Figure 3 Decrease in Brief Psychiatric Rating Scale total scores and negative symptoms subscale scores for prominent negative symptoms and non-prominent negative symptoms. The decrease equals the pre-treatment score minus the post-treatment score at each visit. BPRS: Brief Psychiatric Rating Scale; PNS: Prominent negative symptoms.

Citation: Chen LH, Guo Q, Hu Y, Liu XH, Hu H, Chen HY, Liu CP, Li HF, Chen JD, Li GJ. Effectiveness and safety of blonanserin monotherapy for first-episode schizophrenia with and without prominent negative symptoms: A prospective study. World J Psychiatry 2025; 15(5): 103701
URL: https://www.wjgnet.com/2220-3206/full/v15/i5/103701.htm
DOI: https://dx.doi.org/10.5498/wjp.v15.i5.103701